Date: Thu, 18 Dec 1997 18:02:03 GMT Server: NCSA/1.5.2 Last-modified: Fri, 05 Dec 1997 15:41:39 GMT Content-type: text/html Content-length: 2382
T Cell Sciences, Inc. is a biopharmaceutical company creating value by using novel applications of immunology to prevent and treat cardiovascular, pulmonary and immune disorders. The company is engaged in discovery and early clinical development of three therapeutic programs. The most advanced clinical program focuses on developing compounds that inhibit the inappropriate activation of the complement cascade in a variety of acute and chronic diseases. The company is engaged in the discovery of T cell activation regulators for the prevention of transplant rejection and treatment of autoimmune disorders. The companys third program targets the development of a vaccine for the management of atherosclerosis, one of the leading causes of death in the world.